Synlogic, Inc. (SYBX)
- Previous Close
1.9100 - Open
1.9100 - Bid --
- Ask --
- Day's Range
1.8700 - 1.9100 - 52 Week Range
0.2340 - 5.7080 - Volume
18,879 - Avg. Volume
138,469 - Market Cap (intraday)
21.78M - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-- - EPS (TTM)
-8.8100 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
www.synlogictx.comRecent News: SYBX
Performance Overview: SYBX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SYBX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SYBX
Valuation Measures
Market Cap
21.78M
Enterprise Value
-8.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.61
Price/Book (mrq)
0.51
Enterprise Value/Revenue
-2.58
Enterprise Value/EBITDA
0.16
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.99%
Return on Equity (ttm)
-91.46%
Revenue (ttm)
3.37M
Net Income Avi to Common (ttm)
-57.28M
Diluted EPS (ttm)
-8.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
47.75M
Total Debt/Equity (mrq)
40.50%
Levered Free Cash Flow (ttm)
-22.27M